Skip to main content

Non-vitamin K antagonist oral anticoagulants in cardioversion of atrial fibrillation: a network meta-analysis

Journal of Thrombosis and Thrombolysis volume 46, pages 134–138 (2018)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Gibson CM, Basto AN, Howard ML (2018) Direct oral anticoagulants in cardioversion: a review of current evidence. Ann Pharmacother 52:277–284

    Article  PubMed  CAS  Google Scholar 

  2. Piccini JP, Fauchier L (2016) Rhythm control in atrial fibrillation. Lancet 388:829–840

    Article  PubMed  Google Scholar 

  3. Steffel J, Verhamme P, Potpara TS et al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330–1393

    Article  PubMed  Google Scholar 

  4. Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962

    Article  PubMed  Google Scholar 

  5. January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1–e76

    Article  PubMed  Google Scholar 

  6. Papp J, Zima E, Bover R et al (2017) Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. Eur Heart J Cardiovasc Pharmacother 3:147–150

    Article  PubMed  PubMed Central  Google Scholar 

  7. Brunetti ND, Tarantino N, De Gennaro L et al (2018) Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis. J Thromb Thrombolysis 45:550–556

    Article  PubMed  CAS  Google Scholar 

  8. Ezekowitz MD, Pollack CV, Halperin JL et al (2018) Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. https://doi.org/10.1093/eurheartj/ehy148

    Article  PubMed  PubMed Central  Google Scholar 

  9. Goette A, Merino JL, Ezekowitz MD et al (2016) Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 388:1995–2003

    Article  PubMed  CAS  Google Scholar 

  10. Plitt A, Ezekowitz MD, De Caterina R et al (2016) Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol 39:345–346

    Article  PubMed  Google Scholar 

  11. Flaker G, Lopes RD, Al-Khatib SM et al (2014) Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation). J Am Coll Cardiol 63:1082–1087

    Article  PubMed  CAS  Google Scholar 

  12. Cappato R, Ezekowitz MD, Klein AL et al (2014) Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 35:3346–3355

    Article  PubMed  CAS  Google Scholar 

  13. Piccini JP, Stevens SR, Lokhnygina Y et al (2013) Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 61:1998–2006

    Article  PubMed  CAS  Google Scholar 

  14. Nagarakanti R, Ezekowitz MD, Oldgren J et al (2011) Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 123:131–136

    Article  PubMed  CAS  Google Scholar 

  15. Itäinen S, Lehto M, Vasankari T et al (2017) Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion. Europace 20:565–568

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank Katherine Negele, editorial assistant, research department, Hurley Medical Center, for assistance with manuscript editing.

Author information

Affiliations

  1. Department of Internal Medicine, Hurley Medical Center/Michigan State University, Flint, MI, 48503, USA

    Babikir Kheiri, Tarek Haykal, Ahmed Abdalla, Mohammed Osman, Ghassan Bachuwa & Mustafa Hassan

  2. Flint, MI, USA

    Sahar Ahmed & Khansa Osman

  3. Brigham and Women’s Hospital Heart & Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA

    Deepak L. Bhatt

Authors
  1. Babikir Kheiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tarek Haykal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed Abdalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammed Osman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sahar Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Khansa Osman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ghassan Bachuwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mustafa Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Deepak L. Bhatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deepak L. Bhatt.

Ethics declarations

Conflict of interest

Dr. Mustafa Hassan has received a research grant from Abbott. Dr. Deepak L. Bhatt discloses the following relationships - Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute), Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, PLx Pharma, Takeda.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kheiri, B., Haykal, T., Abdalla, A. et al. Non-vitamin K antagonist oral anticoagulants in cardioversion of atrial fibrillation: a network meta-analysis. J Thromb Thrombolysis 46, 134–138 (2018). https://doi.org/10.1007/s11239-018-1694-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-018-1694-2